These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 16258098

  • 1. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.
    J Clin Oncol; 2005 Nov 01; 23(31):7974-84. PubMed ID: 16258098
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC.
    J Clin Oncol; 2006 Jul 01; 24(19):2991-7. PubMed ID: 16682725
    [Abstract] [Full Text] [Related]

  • 3. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

  • 4. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC.
    J Clin Oncol; 2008 Jan 10; 26(2):290-6. PubMed ID: 18182670
    [Abstract] [Full Text] [Related]

  • 5. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
    Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer-Lung Cancer Group.
    Ann Oncol; 2001 Oct 10; 12(10):1359-68. PubMed ID: 11762805
    [Abstract] [Full Text] [Related]

  • 6. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
    Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, Bréchot JM, Lebeau B.
    Cancer; 1999 Dec 01; 86(11):2238-45. PubMed ID: 10590363
    [Abstract] [Full Text] [Related]

  • 7. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW, Fowler JM, Saltzman AK, Carter JR, Chen MD, Mitchell SK, Dunn D, Carson LF, Adcock LL, Twiggs LB.
    Gynecol Oncol; 1994 Dec 01; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [Abstract] [Full Text] [Related]

  • 8. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR.
    J Clin Oncol; 2004 Aug 15; 22(16):3350-6. PubMed ID: 15310780
    [Abstract] [Full Text] [Related]

  • 9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 15; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF, Krailo M, Chen Z, Feusner J.
    Pediatr Blood Cancer; 2005 Sep 15; 45(3):274-80. PubMed ID: 15806544
    [Abstract] [Full Text] [Related]

  • 11. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW, Treish IM, Zaru L.
    J Oncol Pharm Pract; 2008 Sep 15; 14(3):131-8. PubMed ID: 18524866
    [Abstract] [Full Text] [Related]

  • 12. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T.
    Gan To Kagaku Ryoho; 2003 Jun 15; 30(6):755-9. PubMed ID: 12852340
    [Abstract] [Full Text] [Related]

  • 13. Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
    Bunn PA.
    Ann Oncol; 2001 Oct 15; 12(10):1339-40. PubMed ID: 11762802
    [No Abstract] [Full Text] [Related]

  • 14. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct 15; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U.
    Am J Clin Oncol; 2009 Feb 15; 32(1):61-4. PubMed ID: 19194127
    [Abstract] [Full Text] [Related]

  • 17. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS.
    Eur J Cancer; 2009 Mar 15; 45(4):608-17. PubMed ID: 19110415
    [Abstract] [Full Text] [Related]

  • 18. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F.
    J Clin Oncol; 2005 Oct 01; 23(28):6908-18. PubMed ID: 16129844
    [Abstract] [Full Text] [Related]

  • 19. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN, Tjan-Heijnen VC.
    Anticancer Drugs; 2006 Sep 01; 17(8):881-9. PubMed ID: 16940798
    [Abstract] [Full Text] [Related]

  • 20. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH, Heller G, Kramer K, Cheung NK.
    Cancer; 2000 Nov 15; 89(10):2122-30. PubMed ID: 11066054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.